查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1560205

類毒素疫苗市場報告：2030 年趨勢、預測與競爭分析

Toxoid Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

類毒素疫苗趨勢與預測

到 2030 年，全球類毒素疫苗市場預計將達到 75 億美元，2024 年至 2030 年複合年成長率為 4.5%。該市場的主要促進因素包括感染疾病爆發的增加、新興市場疫苗接種需求的增加以及政府鼓勵疫苗接種的支持措施。全球類毒素疫苗市場的未來充滿希望，醫院、專業機構和政府市場都充滿機會。

Lucintel 預測，由於兒童使用 DTaP 來保護自己免受白喉、破傷風和百日咳等危險疾病的影響，DTaP 在預測期內將出現最高成長。

在這個市場中，由於醫院類毒素疫苗接種的增加，尤其是針對嬰幼兒和孕婦的類毒素疫苗接種，預計醫院在預測期內將出現最高成長。由於人口快速成長和感染疾病患者數量不斷增加，預計亞太地區在預測期內將出現最高的成長。

類毒素疫苗市場的新趨勢

類毒素疫苗市場正在見證許多新興趨勢，包括技術進步、公共衛生優先事項的變化以及疾病概況的變化。這些變化正在影響類毒素疫苗的開發和部署的未來，從而影響市場動態和健康結果。

  • 組合疫苗的優勢日益增強：預防多種疾病的組合類毒素疫苗的開發正在取得進展。這種方法簡化了疫苗接種計劃並提高了公共衛生效率。白喉、破傷風和百日咳的聯合疫苗變得越來越普遍，因為它提供了全面的保護。
  • 佐劑技術的進步：正在開發新的佐劑來增強類毒素疫苗的免疫反應。這些改進旨在提高疫苗的有效性，同時減少所需的注射次數。創新佐劑為疫苗帶來更強、更持久的免疫力。
  • 擴大疫苗的取得範圍：低收入國家正在加強擴大類毒素疫苗的取得範圍。為了縮小發展中國家和富裕國家在醫療保健服務方面的差距並加速全球免疫工作，全球衛生計劃與夥伴關係關係一道，正在努力改善疫苗的分發，重點是提高負擔能力並惠及不符合條件的人群用於疫苗接種。
  • 改進配方的開發：對新疫苗配方的研究仍在繼續，重點是提高安全性和有效性。這包括開發副作用較少的疫苗和改善對特定疾病菌株的保護，從而提高疫苗的整體表現。
  • 數位健康技術的整合：該過程包括將數位健康技術整合到疫苗監測和管理中。這包括使用電子健康記錄和行動應用程式來追蹤疫苗接種計劃、管理不利事件和提高患者依從性，從而實現高效的疫苗接種計劃。

這些趨勢正在改變我們對類毒素疫苗市場的看法，推動創新和增加可及性，同時提高疫苗功效。最終，這將透過更好的疫苗開發和部署程序（包括技術等其他領域）來改善公共衛生結果。

類毒素疫苗市場的最新趨勢

類毒素疫苗市場的最新發展反映了疫苗技術、生產和公共衛生策略的顯著增強。類毒素疫苗可以解決各種健康問題，並且正在提高全世界疫苗的有效性和可近性。

  • 新疫苗配方的增強：此外，正在開發類毒素疫苗的新配方，包括先進的佐劑以及改進的輸送系統，以提高功效，同時減少副作用。這些創新旨在提高疫苗的安全性能。
  • 提高生產能力：疫苗生產設施的擴建和技術的改進正在增加類毒素疫苗的可用性。這涉及改進製造流程以及增加產量以滿足不斷成長的需求。
  • 圍繞疫苗取得的政府措施：世界各國政府正在投資疫苗研究並實施公共衛生計劃，以提高免疫接種的水平。這些舉措的重點是改善疫苗的分發、可負擔性和可近性，特別是對於生活在服務不足地區的人們。
  • 合作研發：製藥公司、研究機構和政府機構之間不斷加強的合作正在推動類毒素疫苗的創新。因此，此類合作夥伴關係正在加速新疫苗的開發並增強這些產品的舊版本。
  • 關注疫苗安全性：因此，正在進行的研究旨在提高類毒素疫苗的安全性和有效性。這些研究也旨在提供有關疫苗接種相關副作用的知識，同時改善整體免疫工作。

最近的這些變化對類毒素疫苗市場產生了重大影響，推動了新穎性、提高了產量並擴大了可用性。這是疫苗技術和公共衛生策略進步的結果，可以更好地預防疾病並改善健康結果。

類毒素疫苗市場的策略性成長機會

類毒素疫苗市場在多種應用領域擁有眾多策略性成長機會。這些機會源自於疫苗技術的進步、疾病盛行率的增加、公共衛生需求的改變。

  • 感染疾病預防：針對白喉、破傷風和百日咳等感染疾病的類毒素疫苗的開發帶來了巨大的成長機會。擴大疫苗接種覆蓋率並改善這些疾病的疫苗接種方案可以改善公共衛生狀況，同時預防疫情爆發。
  • 小兒科免疫 類毒素疫苗在兒科免疫計劃中存在巨大的成長機會。透過開發聯合疫苗來簡化兒童疾病的免疫接種計劃，可以有效應對兒童常見疾病並提高覆蓋率。
  • 旅行者健康：透過向旅行者注射類毒素疫苗，重點關注特定地區和旅行者中流行的疾病，可以獲得成長機會。開發廣泛保護國際旅客的疫苗可以支持全球衛生舉措並改善預期的健康結果。
  • 老年人健康：老年人面臨破傷風等疾病的風險，是類毒素疫苗開發的潛在市場。這些疫苗應專門為老年人設計，以改善該年齡層的疾病預防和健康狀況。

因此，這些機會透過刺激技術創新和擴大應用領域來塑造類毒素疫苗市場。有效抓住這些機會的公司不僅可以從市場擴張中受益，還可以為改善公共衛生做出貢獻。

類毒素疫苗市場促進因素與挑戰

各種技術、經濟和監管因素影響類毒素疫苗市場。了解這些促進因素和問題對於駕馭市場並尋求業務成長機會至關重要。

類毒素疫苗市場的促進因素包括：

1. 技術進步：技術進步：佐劑和遞送系統的改進有助於疫苗技術的擴展。這些突破將提高疫苗的效率和安全性，同時解決新的公共衛生優先事項。

2.疾病增加：由於白喉、破傷風等疾病的流行增加，類毒素疫苗的需求增加。因此，開發有效的疫苗來應對這些對公共衛生和疾病預防的威脅非常重要。

3. 政府投資：市場成長受到政府在疫苗研究、製造和公共衛生計畫的高支出的支持。這就是為什麼要提供資金來提高疫苗的可用性、可負擔性和覆蓋率。

4. 全球衛生工作：國際合作和衛生保健工作正在改善類毒素疫苗的取得。這也包括旨在改善疫苗接種方式和解決健康差異以幫助開拓市場的計劃。

5. 關注疫苗安全性：提高疫苗安全性的研究將決定當今市場趨勢的方向。因此，接種安全有效的疫苗將增強人們接種疫苗的信心，促進疫苗接種。

類毒素疫苗市場面臨的挑戰包括：

1. 高昂的開發成本：製造類毒素疫苗需要研究、臨床試驗和製造成本。價格過高，可能限制市場進入。

2. 監管障礙：疫苗開發可能會受到嚴格的監管要求，並因核准流程而延誤。這並不容易，但必須符合安全標準。

3.供應鏈問題：任何擾亂疫苗供應鏈的因素，從原料短缺到生產延誤，都會影響疫苗的供應和分配。

類毒素疫苗市場受到技術進步、發病率上升和大規模投資的影響。然而，維持市場成長和穩定仍存在許多挑戰，包括高昂的開發成本、監管障礙和供應鏈問題。

類毒素疫苗按市場

本研究按疫苗類型、最終用途和地區對全球類毒素疫苗進行了預測。

類毒素疫苗市場前景（依國家分類）

在疫苗技術、疾病控制策略和公共衛生計畫進步的支持下，類毒素疫苗產業在關鍵地區正在經歷顯著成長。美國、中國、德國、印度和日本的最新進展反映了全球為提高類毒素疫苗的有效性和可及性以創新應對各種健康挑戰所做的努力。

  • 美國：在美國，針對白喉和破傷風等疾病的混合毒力疫苗已取得突破。疫苗配方和輸送系統的創新提高了疫苗功效，同時確保患者遵守規定劑量。除此之外，美國還注重公共衛生計劃的可及性並確保全國範圍內提供最新的有毒疫苗。
  • 中國 中國在開發白喉、破傷風、百日咳等疾病的類毒素疫苗方面取得了顯著進展。這包括提高疫苗生產能力和進行臨床試驗以提高疫苗有效性。中國政府正大力投資疫苗研究和公共衛生基礎設施，擴大疫苗接種覆蓋範圍，同時解決與疫苗相關的新健康問題。
  • 德國 德國類毒素疫苗研究正在取得進展，以期提高疫苗的安全性和有效性。德國強大的法律規範，加上製藥公司和研究機構之間的密切合作，支持類毒素疫苗的創新研發。
  • 印度 印度類毒素疫苗的可及性和可負擔性方面最近取得的進展歸功於各相關人員的努力。除了提高類毒素疫苗的生產能力外，我們也正在開發針對破傷風和白喉等疾病的新疫苗。這主要是透過政府措施以及與國際組織的合作來確保更多印度人接種疫苗而實現的。
  • 日本 在日本，類毒素疫苗的開發正在取得進展，並正在努力改進疫苗的製造方法和安全性。最近，關於新佐劑和遞送系統的研究不斷取得進展，以提高疫苗的有效性。日本類毒素疫苗的開發是由政府機構與 Pharmacology 等私人公司之間的合作所推動的。

常問問題

Q.1 類毒素疫苗的市場規模有多大？

A1. 到 2030 年，全球類毒素疫苗市場預計將達到 75 億美元。

Q.2 類毒素疫苗市場的成長預測如何？

A2. 2024年至2030年，全球類毒素疫苗市場預計將以4.5%的複合年成長率成長。

Q.3 影響類毒素疫苗市場成長的關鍵促進因素有哪些？

A3. 該市場的主要促進因素是感染疾病爆發數量的增加、新興市場疫苗接種需求的增加以及政府鼓勵疫苗接種的支持措施。

Q4.市場的主要細分市場是：

A4. 類毒素疫苗市場前景廣闊，在醫院、專業機構和政府市場都有機會。

Q5.市場的主要企業是：

A5. 生產類毒素疫苗的主要企業如下：

  • Bharat Biotech
  • Ceva
  • GlaxoSmithKline
  • Grifols
  • Zoetis
  • Sanofi
  • Merck & Co
  • Emergent Biosolutions
  • Integrated Biotherapeutics
  • Abbott

Q6. 未來類毒素疫苗的最大市場區隔會是哪一個？

A6.Lucintel 預測 DTaP 在預測期內將出現最高成長，因為它擴大在兒童中使用，以預防白喉、破傷風和百日咳等危險疾病。

Q7. 未來五年類毒素疫苗市場預計成長最快的是哪個地區？

A7.由於人口快速成長和感染疾病患者數量不斷增加，預計亞太地區在預測期內將出現最高成長。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球類毒素疫苗市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球類毒素疫苗市場趨勢（2018-2023）與預測（2024-2030）
  • 按疫苗類型分類的全球類毒素疫苗市場
    • 白喉、破傷風、百日咳 (DTaP)
    • 白喉和破傷風 (DT)
    • 破傷風、白喉和百日咳 (TDaP)
    • 其他
  • 全球類毒素疫苗市場（依最終用途）
    • 醫院
    • 專業中心
    • 政府組織
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球類毒素疫苗市場（按地區）
  • 北美類毒素疫苗市場
  • 歐洲類毒素疫苗市場
  • 亞太類毒素疫苗市場
  • 其他區域類毒素疫苗市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按疫苗類型分類的全球類毒素疫苗市場成長機會
    • 全球類毒素疫苗市場成長機會（依最終用途）
    • 全球類毒素疫苗市場成長機會（按地區）
  • 全球類毒素疫苗市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球類毒素疫苗市場產能擴張
    • 全球類毒素疫苗市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • Bharat Biotech
  • Ceva
    • GlaxoSmithKline
  • Grifols
  • Zoetis
  • Sanofi
  • Merck & Co
  • Emergent BioSolutions
  • Integrated Biotherapeutics
  • Abbott
簡介目錄

Toxoid Vaccine Trends and Forecast

The future of the global toxoid vaccine market looks promising with opportunities in the hospital, specialty centre, and government organization markets. The global toxoid vaccine market is expected to reach an estimated $7.5 billion by 2030 with a CAGR of 4.5% from 2024 to 2030. The major drivers for this market are rising prevalence of infectious diseases, augmenting demand for vaccination in developing countries, and supportive initiatives by the government to encourage immunization.

Lucintel forecasts that DTaP is expected to witness the highest growth over the forecast period due to its growing usage among children to protect against the dangerous illnesses of diphtheria, tetanus, and pertussis.

Within this market, the hospital is expected to witness the highest growth over the forecast period due to the growing number of toxoid vaccinations given out in hospitals, particularly to infants and pregnant women. APAC is expected to witness the highest growth over the forecast period due to the rapid population growth and the rising cases of infectious illnesses among people in the region.

Emerging Trends in the Toxoid Vaccine Market

The toxoid vaccine market is witnessing numerous emerging trends that demonstrate advancements in technology, shifting priorities of public health, and changing disease profiles. These changes are influencing the future of toxoid vaccine development and deployment, with consequent impacts on market dynamics as well as health outcomes.

  • Rising Advantage of Combination Vaccines: There is a movement towards the development of more combination toxoid vaccines meant to protect from several diseases. This approach simplifies immunization schedules and enhances public health efficiency. Combination vaccines for diphtheria, tetanus, and pertussis are becoming more common because they provide all-inclusive coverage.
  • Advances in Adjuvant Technologies: New adjuvants are being developed to boost the immune response of toxoid vaccines. These improvements aim at increasing vaccine effectiveness while reducing number of doses required. Innovative adjuvants introduce to vaccines stronger immunity over a longer period.
  • Vaccine Access Expansion: Efforts aimed at expanding access to toxoid vaccines have been increased in low income countries. Global initiatives for health in conjunction with partnerships focus on improving the distribution, affordability and reaching out those not covered by vaccination interventions across the world in order to reduce disparities in health care provision between developing nations and rich countries that also encourages worldwide immunization efforts.
  • Development of Improved Formulations: Research on the new vaccine formulations is advancing with focus on improving safety and efficacies. This includes development of vaccines with limited side effects and improved protection for certain strains of diseases leading to better overall vaccine performances.
  • Integration of Digital Health Technologies: The process involves integration of digital health technologies into vaccine monitoring and management. They entail use of electronic health records, mobile apps used in tracking vaccination schedules, managing adverse events and improving patient adherence thus leading to efficient vaccination programs.

These trends are changing how we think about toxoid vaccine market by encouraging innovation while improving on the efficacy of vaccines as well as increasing access. Ultimately, this is enhancing public health outcomes through better development and deployment procedures for vaccines that now encompass other areas like technology.

Recent Developments in the Toxoid Vaccine Market

Recent developments in the toxoid vaccine market reflect significant enhancements in vaccine technology, production, and public health strategies. They are addressing different health problems and improving global vaccine efficacy and accessibility.

  • New Enhanced Vaccine Formulations: Besides, newer formulations for toxoid vaccines are being developed which include advanced adjuvants as well as improved delivery systems to improve their effectiveness while reducing side effects. Such innovations aim at enhancing the performance of vaccines with regards to safety profiles.
  • Increased Production Capacities: by expanding vaccine production facilities and upgrading technology this has led to an increase in toxoid vaccines availability. This entails improvements in the manufacturing processes alongside a scale-up of the output to cater for a growing demand.
  • Government Initiatives on Vaccine Access: Governments across the world spend money in research on vaccines and maintain public health programs that will help them widen access levels of these vaccinations. The focus of these initiatives is directed towards bettering vaccine distribution, prices, access especially for those living in underserved regions.
  • Collaborative Research and Development: The increased cooperation between Pharmaceutical companies, research institutions as well as government agencies have propelled innovation regarding toxoid vaccines. Consequently, such alliances accelerate new vaccine development and enhance earlier versions of these products.
  • Vaccines Safety Focus: Therefore, ongoing research aims at improving the safety and efficacy profiles of toxoid vaccines. These studies also seek to provide knowledge about side effects associated with vaccinations while also enhancing overall immunization activities.

These recent changes are having a profound influence in the toxoid vaccine market through pushing on novelty, improving production as well as extending availability. This has been brought about by developments in vaccine technology and public health strategies thus leading to better disease prevention and improved health outcomes.

Strategic Growth Opportunities for Toxoid Vaccine Market

The toxoid vaccine market is experiencing numerous strategic growth opportunities across several applications. These opportunities are due to progress in vaccine technology, increased prevalence of diseases, and changing needs in public health.

  • Infectious Disease Prevention: Developing toxoid vaccines for infectious diseases such as diphtheria, tetanus, and pertussis presents significant growth opportunities. Expanding vaccine coverage and improving vaccine formulas against these conditions can result in a better public health situation while preventing outbreaks.
  • Pediatric Immunization: For the pediatric immunization program, there is a strong growth opportunity for toxoid vaccines. Streamlining immunization schedules for early childhood diseases by developing combination vaccines would address common childhood illnesses effectively and improve coverage.
  • Travel Health: There are growth opportunities by targeting travelers with toxoid vaccines focusing on particular regions or diseases prevalent among them. Creating vaccines that offer broad protection to international travelers can support global health initiatives and thus enhance their expected health outcomes.
  • Elderly Health: The elderly are at risk of diseases such as tetanus, which presents a potential market for the development of toxoid vaccines. These vaccines should be designed specifically for the older population to have disease prevention improvements and better health outcomes within this age bracket

As a result, these opportunities are responsible for the shaping of the toxoid vaccine market through stimulating innovation and extending its areas of application. Those firms that will effectively address them will benefit from market expansion as well as contribute to better public health.

Toxoid Vaccine Market Driver and Challenges

Various technological, economic, and regulatory factors affect the toxoid vaccine market. Knowing what propels and poses a problem in these is crucial to steer through the market while seeking business growth opportunities.

The factors responsible for driving the toxoid vaccine market include:

1. Advances in Technology: Improved adjuvants and delivery systems are contributing to the expansion of vaccine technology. These breakthroughs enhance the efficiency and safety of vaccines while addressing emerging public health priorities.

2. Increasing Disease Prevalence: The increasing prevalence of diseases like diphtheria and tetanus has led to a growing demand for toxoid vaccines. Consequently, it is important to develop efficient vaccines against these threats to public health and disease prevention.

3. Government Investment: Market growth is supported by heavy government spending on vaccine research, production, and public health programs. Thus, funding initiatives are designed to improve the accessibility, affordability, and coverage of vaccines.

4. Global Health Initiatives: International cooperation as well as healthcare initiatives have improved access to toxoid vaccines. This further includes programs that seek improving distribution methods for immunizations and tackling health disparities which contribute towards market development.

5. Vaccine Safety Emphasis: Research aimed at improving vaccine safety dictates the course market trends are taking today. Thus having safe and effective vaccines builds confidence among people about immunization thus promoting their uptake.

Challenges in the toxoid vaccine market are:

1. Exorbitant Development Expenses: The production of toxoid vaccines is associated with research, clinical trials, and manufacturing costs. The price can be prohibitive and hence limit market entry.

2. Regulatory Barriers: Vaccine development can be slowed down by strict regulatory requirements and approval processes. It may not be easy but it has to comply with safety standards.

3. Problems With Supply Chain: Anything that disrupts the supply chain for vaccines from raw material shortage to production delays will have an influence on vaccine availability and distribution.

The toxoid vaccine market is influenced by the advances in technology, increasing rates of diseases and large investment. However, to maintain the growth and stability of the market, there still exist a number of challenges that includes high cost of development, regulatory barriers as well as supply chain issues.

List of Toxoid Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies toxoid vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the toxoid vaccine companies profiled in this report include-

  • Bharat Biotech
  • Ceva
  • GlaxoSmithKline
  • Grifols
  • Zoetis
  • Sanofi
  • Merck & Co
  • Emergent Biosolutions
  • Integrated Biotherapeutics
  • Abbott

Toxoid Vaccine by Segment

The study includes a forecast for the global toxoid vaccine by vaccine type, end use, and region.

Toxoid Vaccine Market by Vaccine Type [Analysis by Value from 2018 to 2030]:

  • Diphtheria, Tetanus, and Pertussis (DTaP)
  • Diphtheria and Tetanus (DT)
  • Tetanus, Diphtheria, and Pertussis (TDaP)
  • Others

Toxoid Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Centre
  • Governments Organization
  • Others

Toxoid Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Toxoid Vaccine Market

The toxoid vaccine industry has progressed significantly in major regions, supported by advancements in vaccine technology, disease management strategies, and public health programs. The recent developments seen in the United States, China, Germany, India, and Japan are a reflection of worldwide efforts towards increased toxoid vaccine effectiveness and accessibility with innovative responses to different health challenges.

  • United States: In the USA there have been breakthroughs such as combined toxic vaccines for diseases like diphtheria and tetanus. Innovations in vaccine formulations and delivery systems have improved the efficacy of vaccines while at the same time ensuring that patients adhere to prescribed dosages. Besides this, the US is also focusing on accessing public health programs and ensuring the availability of updated toxic vaccines nationwide.
  • China: China has made remarkable achievements in toxoid vaccine development for instance diphtheria tetanus pertussis. These include improving vaccine production capacity as well as carrying out clinical trials to boost the efficacy of vaccines. The Chinese government has invested heavily in vaccine research and public health infrastructure that would expand coverage of vaccination while tackling emerging health issues related to it.
  • Germany: Germany's toxoid vaccine research is progressing with a view to improving vaccine safety and efficacy. This has seen the introduction of new formulations and adjuvants aimed to improve immune responses. robustness of Germany's regulatory framework, which involves close cooperation between pharmaceutical companies and research institutions, supports innovative developments in toxoid vaccines.
  • India: Recent advances that have been made regarding the accessibility and affordability concerns surrounding toxoid vaccines in India have been an effort by various stakeholders. The country is increasing its ability to produce these vaccines as well as creating new ones for example tetanus and diphtheria. This has mainly been made possible through government initiatives as well as partnering with international organizations to ensure that more Indian population are immunized.
  • Japan: In Japan, there has been progress in toxoid vaccines aiming at improving vaccine formulation and safety issues. Recently, some of the advancements include studying new adjuvants and delivery systems for enhanced vaccine effectiveness. Toxoid vaccine development in Japan is driven by public health commitment that exist within both the government departments and also from collaboration between these agencies together with private sectors such as pharmacology firms.

Features of the Global Toxoid Vaccine Market

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Toxoid vaccine market size by vaccine type, end use, and region in terms of value ($B).

Regional Analysis: Toxoid vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different vaccine types, end uses, and regions for the toxoid vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the toxoid vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the toxoid vaccine market size?

Answer: The global toxoid vaccine market is expected to reach an estimated $7.5 billion by 2030.

Q.2 What is the growth forecast for toxoid vaccine market?

Answer: The global toxoid vaccine market is expected to grow with a CAGR of 4.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the toxoid vaccine market?

Answer: The major drivers for this market are rising prevalence of infectious diseases, augmenting demand for vaccination in developing countries and, supportive initiatives by the government to encourage immunization.

Q4. What are the major segments for toxoid vaccine market?

Answer: The future of the toxoid vaccine market looks promising with opportunities in the hospital, specialty centre, and government organization markets.

Q5. Who are the key toxoid vaccine market companies?

Answer: Some of the key toxoid vaccine companies are as follows:

  • Bharat Biotech
  • Ceva
  • GlaxoSmithKline
  • Grifols
  • Zoetis
  • Sanofi
  • Merck & Co
  • Emergent Biosolutions
  • Integrated Biotherapeutics
  • Abbott

Q6. Which toxoid vaccine market segment will be the largest in the future?

Answer: Lucintel forecasts that DTaP is expected to witness the highest growth over the forecast period due to its growing usage among children to protect against the dangerous illnesses of diphtheria, tetanus, and pertussis.

Q7. In toxoid vaccine market, which region is expected to be the largest in the next 5 years?

Answer: APAC is expected to witness the highest growth over the forecast period due to the rapid population growth and the rising cases of infectious illnesses among people in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the toxoid vaccine market by vaccine type (diphtheria, tetanus, and pertussis (DTaP), diphtheria and tetanus (DT), tetanus, diphtheria, and pertussis (TDaP), and others), end use (hospitals, specialty centre, governments organization, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Toxoid Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Toxoid Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Toxoid Vaccine Market by Vaccine Type
    • 3.3.1: Diphtheria, Tetanus, and Pertussis (DTaP)
    • 3.3.2: Diphtheria and Tetanus (DT)
    • 3.3.3: Tetanus, Diphtheria, and Pertussis (TDaP)
    • 3.3.4: Others
  • 3.4: Global Toxoid Vaccine Market by End Use
    • 3.4.1: Hospitals
    • 3.4.2: Specialty Centre
    • 3.4.3: Governments Organization
    • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Toxoid Vaccine Market by Region
  • 4.2: North American Toxoid Vaccine Market
    • 4.2.1: North American Toxoid Vaccine Market by Vaccine Type: Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), Tetanus, Diphtheria, and Pertussis (TDaP), and Others 4.2.2: North American Toxoid Vaccine Market by End Use: Hospitals, Specialty Centre, Governments Organization, and Others
  • 4.3: European Toxoid Vaccine Market
    • 4.3.1: European Toxoid Vaccine Market by Vaccine Type: Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), Tetanus, Diphtheria, and Pertussis (TDaP), and Others
    • 4.3.2: European Toxoid Vaccine Market by End Use: Hospitals, Specialty Centre, Governments Organization, and Others
  • 4.4: APAC Toxoid Vaccine Market
    • 4.4.1: APAC Toxoid Vaccine Market by Vaccine Type: Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), Tetanus, Diphtheria, and Pertussis (TDaP), and Others
    • 4.4.2: APAC Toxoid Vaccine Market by End Use: Hospitals, Specialty Centre, Governments Organization, and Others
  • 4.5: ROW Toxoid Vaccine Market
    • 4.5.1: ROW Toxoid Vaccine Market by Vaccine Type: Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), Tetanus, Diphtheria, and Pertussis (TDaP), and Others
    • 4.5.2: ROW Toxoid Vaccine Market by End Use: Hospitals, Specialty Centre, Governments Organization, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Toxoid Vaccine Market by Vaccine Type
    • 6.1.2: Growth Opportunities for the Global Toxoid Vaccine Market by End Use
    • 6.1.3: Growth Opportunities for the Global Toxoid Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Toxoid Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Toxoid Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Toxoid Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bharat Biotech
  • 7.2: Ceva
    • 7.1.1: GlaxoSmithKline
  • 7.4: Grifols
  • 7.5: Zoetis
  • 7.6: Sanofi
  • 7.7: Merck & Co
  • 7.8: Emergent BioSolutions
  • 7.9: Integrated Biotherapeutics
  • 7.10: Abbott